Scarica l'app Stockscreener
12.98
4.34%
0.54
Precedente Chiudi:
$12.44
Aprire:
$12.35
Volume 24 ore:
20,178
Relative Volume:
0.89
Capitalizzazione di mercato:
$29.50M
Reddito:
-
Utile/perdita netta:
$-4.85M
Rapporto P/E:
-41.87
EPS:
-0.31
Flusso di cassa netto:
$-3.95M
1 W Prestazione:
+26.26%
1M Prestazione:
-5.19%
6M Prestazione:
-18.11%
1 anno Prestazione:
+79.46%
Intervallo 1D:
$12.04
$13.24
Intervallo di 1 settimana:
$10.11
$13.71
Portata 52W:
$5.70
$22.90
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Nome
Cadrenal Therapeutics Inc
Settore
Industria
Telefono
904-300-0701
Indirizzo
822 A1A NORTH, PONTE VEDRA
Confronta CVKD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
12.98 | 29.50M | 0 | -4.85M | -3.95M | -0.31 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-18 | Iniziato | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Borsa (CVKD) Ultime notizie
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Down 0.1% – Here’s What Happened - Defense World
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients - BioSpace
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 - BioSpace
(CVKD) Technical Pivots with Risk Controls - news.stocktradersdaily.com
What is Zacks Small Cap’s Estimate for CVKD FY2025 Earnings? - Defense World
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin… - MSN
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin - research-tree.com
Cadrenal Therapeutics (NASDAQ:CVKD) Earns Buy Rating from HC Wainwright - Defense World
(CVKD) Proactive Strategies - news.stocktradersdaily.com
Positive Outlook for Cadrenal Therapeutics, Inc. Amid Strategic Developments and FDA Trial Milestone - TipRanks
Cadrenal Therapeutics (CVKD) Receives Buy Rating from HC Wainwright & Co. | CVKD Stock News - GuruFocus
Cadrenal Therapeutics advances in tecarfarin production By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics advances in tecarfarin production - Investing.com
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness - Business Wire
Cadrenal Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 forNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 - openPR.com
Shares Of This EV Stock Soar On Year-Over-Year Guidance - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) - The Globe and Mail
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) | FinancialContent - FinancialContent
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thinner, Less Problematic Than Warfrain: $CVKD | FinancialContent - FinancialContent
Cisco Expands Partnership with Saudi Arabia to Power the AI Future - The Globe and Mail
PRN_FinancialWrapper - FinancialContent
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
CADRENAL THERAPEUTICS Earnings Preview: Recent $CVKD Insider Trading, Hedge Fund Activity, and More - Nasdaq
10,554 Shares in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Purchased by Geode Capital Management LLC - Defense World
Cadrenal Therapeutics (CVKD) to Release Quarterly Earnings on Thursday - Defense World
Sprott Asset Management buying more Sprott Phys. Copper Trust (COP) - The Globe and Mail
Cadrenal Therapeutics (NASDAQ:CVKD) Shares Up 0.8% – Here’s Why - Defense World
Trading (CVKD) With Integrated Risk Controls - news.stocktradersdaily.com
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq - BioSpace
Cadrenal Therapeutics Reveals Latest Phase 3 Anticoagulant Progress at Exclusive Nasdaq Conference - Stock Titan
Cadrenal Therapeutics IncFiles Prospectus Supplement For $2.17 Million ATM Offering - marketscreener.com
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans? - Yahoo
When (CVKD) Moves Investors should Listen - news.stocktradersdaily.com
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences - BioSpace
Cadrenal Takes Center Stage: Key Executives to Showcase Novel Anticoagulant at Industry-Leading Events - Stock Titan
Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap - Defense World
(CVKD) Trading Advice - Stock Traders Daily
Altimmune to put its incretin into addiction trials; Tarsus aims to raise $125M - Endpoints News
Cadrenal Therapeutics Advances Tecarfarin Development in 2024 - TipRanks
Cadrenal Therapeutics Reports Full Year 2024 Results - TradingView
Cadrenal Therapeutics, Inc. SEC 10-K Report - TradingView
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin - Bluefield Daily Telegraph
Cadrenal Secures FDA Orphan Drug Status and Abbott Partnership for Breakthrough Phase 3 Trial - StockTitan
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial - Research Tree
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Yahoo Finance
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial - TipRanks
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Yahoo Finance
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD - BioSpace
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug -March 04, 2025 at 08:53 am EST - Marketscreener.com
Cadrenal Therapeutics Inc Azioni (CVKD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):